首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1812457

内分泌治疗市场按治疗领域、给药途径、年龄层、分销管道、最终用户和地区划分

Endocrinology Drug Market, By Therapy Area, By Route of Administration, By Age Group, By Distribution Channel, By End User, By Geography

出版日期: 2025年08月20日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3个工作天内

价格

简介目录

内分泌治疗市场规模预计在 2025 年达到 741.1 亿美元，预计在 2032 年达到 995.1 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 4.3%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	741.1亿美元
效能数据	2020年至2024年	预测期	2020年至2024年
预测期：2025-2032年复合年增长率：	4.30%	2032年的价值预测	995.1亿美元

全球内分泌治疗市场是治疗荷尔蒙和代谢失调的重要领域，这些失调影响着全球数百万人。内分泌学涵盖荷尔蒙分泌腺体及其相关疾病的研究，包括糖尿病、甲状腺功能障碍、生长激素缺乏症、骨质疏鬆症、肥胖症和生殖激素失衡。在生物技术、个人化医疗方法和创新药物传输系统的推动下，该领域的药物正在经历重大变化。

现代内分泌治疗药物涵盖多种类别，包括胰岛素类似物、GLP-1受体促效剂、SGLT-2抑制剂、甲状腺激素替代药物、双磷酸盐和荷尔蒙补充疗法。市场复杂性源自于患者族群多样化，需要客製化治疗方法，涵盖从儿童生长迟缓到老年代谢疾病等各种疾病。持续血糖监测、智慧胰岛素输送系统和生物标记主导诊断领域的技术创新正在彻底改变治疗模式，并推动精准医疗方法的发展。此外，与生活方式相关的内分泌疾病（尤其是糖尿病和肥胖症）的盛行率日益上升，推动了研究投入和监管重点的增加，以开发疗效更佳、副作用更少的下一代疗法。

市场动态

全球内分泌治疗市场正经历强劲成长，这得益于多种相互关联的因素。一个关键的市场驱动力是全球糖尿病盛行率的上升，目前糖尿病影响着超过5亿人，对创新的血糖管理解决方案、胰岛素疗法和联合治疗的需求庞大。人口老化是市场扩张的主要原因，因为老年人口更容易患甲状腺疾病、骨质疏鬆症和荷尔蒙失衡，需要长期药物介入。药物製剂的技术进步，例如缓释性机制、生物相似药开发和新型给药系统，正在推动市场创新，同时提高患者的依从性和治疗效果。

然而，市场发展面临着巨大的限制，包括严格的监管核准流程，这延迟了产品的上市，并增加了开发成本，尤其是对于复杂的生技药品和联合治疗。重磅内分泌治疗药物的专利到期，给原研公司带来了定价压力，并侵蚀了市场份额，而医疗成本控制措施则影响了全球的报销政策和药物的可及性。

此外，生物製药的生产复杂性、供应链脆弱性和品管要求也带来了营运挑战。即便如此，新兴经济体中尚未开发的市场仍可能蕴藏着巨大的商机。这些市场的糖尿病和代谢性疾病病例正在迅速增加，但治疗渗透率却较低。利用基因检测和生物标记识别的个人化医疗方法为标靶治疗带来了丰厚的前景。包括远端医疗平台和人工智慧驱动的治疗优化在内的数位健康整合正在创造新的收益来源并增强病人参与，使内分泌治疗市场在面临挑战的情况下仍能保持持续成长。

本次调查的主要特点

本报告对全球内分泌治疗市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它强调了各个领域的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球内分泌治疗市场的主要企业。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。
本报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球内分泌治疗市场的各种策略矩阵更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 74.11 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	4.30%	2032 Value Projection:	USD 99.51 Bn

The global endocrinology drug market represents a critical therapeutic segment addressing hormonal disorders and metabolic diseases that affect millions worldwide. Endocrinology encompasses the study of hormone-producing glands and their associated disorders, including diabetes mellitus, thyroid dysfunction, growth hormone deficiencies, osteoporosis, obesity, and reproductive hormone imbalances. The pharmaceutical landscape within this domain has witnessed remarkable evolution, driven by advancing biotechnology, personalized medicine approaches, and innovative drug delivery systems.

Modern endocrinology therapeutics span across various drug classes including insulin analogues, GLP-1 receptor agonists, SGLT-2 inhibitors, thyroid hormone replacements, bisphosphonates, and hormone replacement therapies. The market's complexity stems from diverse patient populations requiring tailored treatment regimens, ranging from pediatric growth disorders to geriatric metabolic conditions. Technological breakthroughs in continuous glucose monitoring, smart insulin delivery systems, and biomarker-driven diagnostics have revolutionized treatment paradigms, enabling precision medicine approaches. Additionally, the growing prevalence of lifestyle-related endocrine disorders, particularly diabetes and obesity, has intensified research investments and regulatory focus on developing next-generation therapeutics with improved efficacy profiles and reduced adverse effects.

Market Dynamics

The global endocrinology drug market experiences robust growth driven by multiple interconnected factors that shape its trajectory. Primary market drivers include the escalating prevalence of diabetes worldwide, with over 500 million affected individuals creating substantial demand for innovative glucose management solutions, insulin therapies, and combination treatments. Aging demographics contribute significantly to market expansion as elderly populations exhibit higher susceptibility to thyroid disorders, osteoporosis, and hormonal imbalances requiring long-term pharmaceutical interventions. Technological advancements in drug formulation, including extended-release mechanisms, biosimilar development, and novel delivery systems, drive market innovation while improving patient compliance and therapeutic outcomes.

However, the market growth faces considerable restraints including stringent regulatory approval processes that delay product launches and increase development costs, particularly for complex biologics and combination therapies. Patent expirations of blockbuster endocrinology drugs create pricing pressures and market share erosion for originator companies, while healthcare cost containment measures globally impact reimbursement policies and accessibility.

Additionally, manufacturing complexities associated with biologic drugs, supply chain vulnerabilities, and quality control requirements pose operational challenges. Nevertheless, significant opportunities emerge through untapped markets in developing economies where diabetes and metabolic disorders are rapidly increasing but treatment penetration remains low. Personalized medicine approaches leveraging genetic testing and biomarker identification present lucrative prospects for targeted therapeutics. Digital health integration, including telemedicine platforms and AI-driven treatment optimization, creates new revenue streams and enhances patient engagement, positioning the endocrinology drug market for sustained growth despite existing challenges.

Key features of the study

This report provides in-depth analysis of the global endocrinology drug market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global endocrinology drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Pfizer Inc, Merck & Co Inc, Novartis AG, AstraZeneca plc, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Ipsen Pharma, Teva Pharmaceutical Industries Ltd, Amgen Inc, and Bayer AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global endocrinology drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global endocrinology drug market

Market Segmentation

Therapy Area Insights (Revenue, USD Bn, 2020 - 2032)
- Diabetes Management Drugs
- Insulin (short-acting, long-acting, and premixed)
- Oral Antidiabetics (biguanides, sulfonylureas, thiazolidinediones, etc.)
- GLP-1 Receptor Agonists
- Other Combination Therapies
- Thyroid Disorder Drugs
- Hypothyroidism Treatments (levothyroxine and liothyronine)
- Hyperthyroidism Treatments (antithyroid drugs and radioiodine therapy adjuncts)
- Growth Hormone Related Drugs
- Growth Hormone Deficiency Treatments (recombinant growth hormones, etc.)
- Acromegaly Treatments (somatostatin analogs, GH receptor antagonists, etc.)
- Adrenal Disorder Drugs
- Cushing's Syndrome Treatments (steroidogenesis inhibitors, pituitary-targeted drugs)
- Addison's Disease Treatments (glucocorticoids and mineralocorticoids)
- Congenital Adrenal Hyperplasia Drugs
- Reproductive Endocrinology Drugs
- Men's Health (testosterone therapies and anti-androgens)
- Women's Health (estrogen therapies, progesterone therapies, etc.)
- Fertility Drugs (gonadotropins, ovulation stimulants, etc.)
- Calcium and Bone Metabolism Drugs
- Osteoporosis Treatments (bisphosphonates, SERMs, calcitonin, etc.)
- Hyperparathyroidism Treatments (calcimimetics, vitamin D analogs, etc.)
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Transdermal (patches and gels)
- Nasal
- Others (e.g., sublingual, rectal)
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Specialty Endocrine Centers
- Ambulatory Surgical Centers (ASCs)
- Homecare Settings
- Others (Academic and Research Institutes, etc.)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- Pfizer Inc
- Merck & Co Inc
- Novartis AG
- AstraZeneca plc
- AbbVie Inc
- Takeda Pharmaceutical Company Limited
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd
- Amgen Inc
- Bayer AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Endocrinology Drug Market, By Therapy Area
- Global Endocrinology Drug Market, By Route of Administration
- Global Endocrinology Drug Market, By Age Group
- Global Endocrinology Drug Market, By Distribution Channel
- Global Endocrinology Drug Market, By End User
- Global Endocrinology Drug Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Endocrinology Drug Market, By Therapy Area, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Diabetes Management Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Insulin (short-acting, long-acting and premixed)
  - Oral Antidiabetics (biguanides, sulfonylureas, thiazolidinediones, etc.)
  - GLP-1 Receptor Agonists
  - Other Combination Therapies
Thyroid Disorder Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Hypothyroidism Treatments (levothyroxine and liothyronine)
  - Hyperthyroidism Treatments (antithyroid drugs and radioiodine therapy adjuncts)
Growth Hormone Related Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Growth Hormone Deficiency Treatments (recombinant growth hormones, etc.)
  - Acromegaly Treatments (somatostatin analogs, GH receptor antagonists, etc.)
Adrenal Disorder Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Cushing's Syndrome Treatments (steroidogenesis inhibitors, pituitary-targeted drugs)
  - Addison's Disease Treatments (glucocorticoids, mineralocorticoids)
  - Congenital Adrenal Hyperplasia Drugs
Reproductive Endocrinology Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Men's Health (testosterone therapies and anti-androgens)
  - Women's Health (estrogen therapies, progesterone therapies, etc.)
  - Fertility Drugs (gonadotropins, ovulation stimulants, etc.)
Calcium and Bone Metabolism Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Osteoporosis Treatments (bisphosphonates, SERMs, calcitonin, etc.)
  - Hyperparathyroidism Treatments (calcimimetics, vitamin D analogs, etc.)

5. Global Endocrinology Drug Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Transdermal (patches and gels)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (e.g., sublingual and rectal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Endocrinology Drug Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Endocrinology Drug Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Endocrinology Drug Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Endocrine Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Endocrinology Drug Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

11. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

12. References and Research Methodology

References
Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/价格

内分泌治疗市场按治疗领域、给药途径、年龄层、分销管道、最终用户和地区划分

Endocrinology Drug Market, By Therapy Area, By Route of Administration, By Age Group, By Distribution Channel, By End User, By Geography

市场动态

目录

第 1 章：调查目标与先决条件

第二章市场展望

第三章：市场动态、法规与趋势分析

4. 2020-2032 年全球内分泌治疗市场（依治疗领域）

5. 2020-2032 年全球内分泌治疗市场（依给药途径）

6. 2020-2032 年全球内分泌治疗市场（依年龄层）

7. 2020-2032 年全球内分泌治疗市场（依通路）

8. 2020-2032 年全球内分泌治疗市场（依最终使用者划分）

9. 2020-2032 年全球内分泌治疗市场（按地区）

第十章竞争格局

第 11 章分析师建议

第十二章参考文献与调查方法